See more : Freightways Group Limited (FRW.NZ) Income Statement Analysis – Financial Results
Complete financial analysis of Anixa Biosciences, Inc. (ANIX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Anixa Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- California First Leasing Corporation (CFNB) Income Statement Analysis – Financial Results
- First National of Nebraska, Inc. (FINN) Income Statement Analysis – Financial Results
- Densan Co., Ltd. (3640.T) Income Statement Analysis – Financial Results
- Qingdao TGOOD Electric Co., Ltd. (300001.SZ) Income Statement Analysis – Financial Results
- Ternium S.A. (TX) Income Statement Analysis – Financial Results
Anixa Biosciences, Inc. (ANIX)
About Anixa Biosciences, Inc.
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 210.00K | 2.47B | 512.50K | 0.00 | 250.00K | 1.11M | 362.50K | 300.00K | 9.26M | 3.67M | 388.85K | 940.01K | 1.00M | 730.68K | 1.06M | 2.06M | 486.85K | 508.65K | 439.79K | 494.46K | 244.22K | 5.19M | 1.69M | 1.47M | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 300.00K |
| Cost of Revenue | 161.00K | 42.00K | 385.00K | 90.16K | 166.25K | 768.41K | 104.56K | 217.42K | 3.65M | 1.99M | 316.66K | 3.87K | 34.08K | 82.31K | 65.69K | 95.59K | 160.36K | 156.45K | 719.63K | 176.11K | 175.94K | 1.87M | 697.64K | 463.63K | -300.00K | -300.00K | -300.00K | -100.00K | -100.00K | -100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 49.00K | 2.47B | 127.50K | -90.16K | 83.75K | 344.09K | 257.94K | 82.58K | 5.61M | 1.68M | 72.19K | 936.14K | 969.11K | 648.37K | 990.11K | 1.97M | 326.49K | 352.21K | -279.84K | 318.35K | 68.28K | 3.32M | 993.13K | 1.01M | 400.00K | 400.00K | 400.00K | 200.00K | 200.00K | 200.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 300.00K |
| Gross Profit Ratio | 23.33% | 100.00% | 24.88% | 0.00% | 33.50% | 30.93% | 71.16% | 27.53% | 60.58% | 45.79% | 18.57% | 99.59% | 96.60% | 88.74% | 93.78% | 95.37% | 67.06% | 69.24% | -63.63% | 64.38% | 27.96% | 63.93% | 58.74% | 68.50% | 400.00% | 400.00% | 400.00% | 200.00% | 200.00% | 200.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 4.77M | 6.70M | 6.19M | 4.38M | 5.47M | 6.81M | 1.60M | 1.56M | 711.39K | 1.19M | 0.00 | 2.21M | 3.12M | 3.01M | 4.12M | 4.13M | 3.40M | 4.61M | 2.27M | 2.16M | 1.81M | 1.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.90M | 2.40M | 2.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.29M | 7.17M | 7.07M | 5.60M | 5.66M | 6.91M | 4.41M | 2.71M | 5.51M | 6.41M | 7.99M | 2.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.29M | 7.17M | 7.07M | 5.60M | 5.66M | 6.91M | 4.41M | 2.71M | 5.51M | 6.41M | 7.99M | 2.86M | 2.87M | 2.89M | 4.19M | 3.83M | 2.41M | 3.37M | 1.92M | 1.52M | 1.38M | 2.18M | 4.60M | 5.83M | 8.30M | 7.20M | 6.40M | 2.20M | 1.00M | 1.00M | 2.90M | 2.00M | 1.50M | 1.40M | 1.20M | 1.30M | 1.30M | 1.90M | 2.00M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 418.75K | 0.00 | -13.10K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 47.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 11.06M | 13.88M | 13.26M | 9.98M | 11.56M | 14.05M | 6.33M | 4.59M | 6.55M | 6.72M | 7.99M | 5.07M | 6.00M | 5.90M | 8.31M | 7.96M | 5.53M | 7.98M | 4.19M | 3.68M | 3.19M | 6.62M | 4.60M | 6.09M | 8.60M | 7.50M | 6.70M | 6.20M | 3.50M | 3.80M | 2.90M | 2.00M | 1.50M | 1.50M | 1.30M | 1.40M | 1.40M | 1.90M | 2.00M |
| Cost & Expenses | 11.22M | 13.88M | 13.65M | 9.98M | 11.72M | 14.82M | 6.44M | 4.81M | 10.20M | 8.71M | 8.31M | 5.07M | 6.03M | 5.98M | 8.38M | 8.05M | 5.69M | 8.14M | 4.91M | 3.86M | 3.36M | 8.50M | 5.30M | 6.56M | 8.30M | 7.20M | 6.40M | 6.10M | 3.40M | 3.70M | 2.90M | 2.00M | 1.50M | 1.50M | 1.30M | 1.40M | 1.40M | 1.90M | 2.00M |
| Interest Income | 1.08M | 104.00K | 2.32K | 33.92K | 71.35K | 45.97K | 19.44K | 12.53K | 17.62K | 8.60K | 125.00 | 3.46K | 2.52K | 4.88K | 20.81K | 37.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 104.00K | 322.00 | 0.00 | 0.00 | 0.00 | 500.46K | 519.95K | 451.91K | 1.26M | 1.11M | 7.66K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 46.00K | 42.00K | 59.86K | 90.16K | 466.31K | 343.73K | 368.51K | 358.63K | 337.81K | 314.45K | 125.00 | 7.23K | 7.98K | 8.36K | 10.61K | 10.67K | 9.89K | 15.07K | 14.71K | 17.00K | 33.08K | 86.47K | 166.50K | 261.80K | 300.00K | 300.00K | 300.00K | 100.00K | 100.00K | 100.00K | -200.00K | -200.00K | -200.00K | 100.00K | 100.00K | 100.00K | 100.00K | 0.00 | 0.00 |
| EBITDA | -10.97M | -13.73M | -13.08M | -10.00M | -11.00M | -13.36M | -4.14M | -4.14M | -601.85K | -8.03M | -8.97M | -4.24M | -6.77M | -5.25M | -7.32M | -5.98M | -5.45M | -7.61M | -4.45M | -3.35M | -3.09M | -3.22M | -3.44M | -4.82M | -7.90M | -6.80M | -6.00M | -5.90M | -3.20M | -3.50M | -3.00M | -2.10M | -1.60M | -1.30M | -1.10M | -1.20M | -1.20M | -1.80M | -1.70M |
| EBITDA Ratio | -5,221.43% | -0.56% | -2,552.44% | 0.00% | -4,234.48% | -1,148.71% | -1,569.00% | -1,379.28% | -6.37% | -128.73% | -2,036.14% | -439.47% | -500.18% | -726.46% | 178.05% | -296.14% | -1,065.76% | -1,496.61% | -1,012.10% | -677.10% | -1,263.61% | -7.74% | -203.32% | -327.67% | -7,600.00% | -6,900.00% | -6,600.00% | -6,500.00% | -3,600.00% | -3,700.00% | -3,000.00% | -2,100.00% | -1,600.00% | -1,600.00% | -1,300.00% | -1,300.00% | -1,200.00% | -1,800.00% | -566.67% |
| Operating Income | -11.01M | -13.88M | -13.14M | -9.98M | -11.47M | -14.29M | -6.08M | -4.51M | -944.76K | -5.04M | -7.92M | -4.13M | -5.03M | -5.25M | -7.32M | -5.99M | -5.49M | -7.63M | -4.47M | -3.36M | -3.12M | -3.31M | -3.60M | -5.09M | -8.20M | -7.10M | -6.30M | -6.00M | -3.30M | -3.60M | -2.80M | -1.90M | -1.40M | -1.40M | -1.20M | -1.30M | -1.30M | -1.80M | -1.70M |
| Operating Income Ratio | -5,243.33% | -0.56% | -2,563.06% | 0.00% | -4,588.50% | -1,284.41% | -1,676.02% | -1,503.00% | -10.21% | -137.54% | -2,036.17% | -439.84% | -501.23% | -718.27% | -693.35% | -290.31% | -1,128.14% | -1,499.58% | -1,015.44% | -680.54% | -1,277.15% | -63.79% | -213.17% | -345.46% | -8,200.00% | -7,100.00% | -6,300.00% | -6,000.00% | -3,300.00% | -3,600.00% | -2,800.00% | -1,900.00% | -1,400.00% | -1,400.00% | -1,200.00% | -1,300.00% | -1,300.00% | -1,800.00% | -566.67% |
| Total Other Income/Expenses | 1.08M | 104.00K | 7.69K | -114.16K | 71.35K | 45.97K | 1.07M | -507.42K | -434.28K | -4.56M | -2.16M | -118.24K | -1.75M | 73.09K | -9.17M | 167.91K | 34.15K | 26.72K | 14.51K | 4.33K | 0.00 | -2.82M | 0.00 | 0.00 | -300.00K | 100.00K | 600.00K | 600.00K | 400.00K | 200.00K | 200.00K | 200.00K | 200.00K | 300.00K | 200.00K | 100.00K | 0.00 | 1.80M | 1.70M |
| Income Before Tax | -9.93M | -13.77M | -13.13M | -10.09M | -11.82M | -14.24M | -5.01M | -5.02M | -1.38M | -9.61M | -10.08M | -4.25M | -6.78M | -5.18M | -16.49M | -5.82M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -6.13M | 0.00 | 0.00 | -8.50M | -7.00M | -5.70M | -5.40M | -2.90M | -3.40M | -2.60M | -1.70M | -1.20M | -1.10M | -1.00M | -1.20M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -4,728.57% | -0.56% | -2,561.55% | 0.00% | -4,727.46% | -1,280.28% | -1,381.79% | -1,672.14% | -14.90% | -261.94% | -2,592.28% | -452.42% | -675.65% | -708.27% | -1,561.76% | -282.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -118.18% | 0.00% | 0.00% | -8,500.00% | -7,000.00% | -5,700.00% | -5,400.00% | -2,900.00% | -3,400.00% | -2,600.00% | -1,700.00% | -1,200.00% | -1,100.00% | -1,000.00% | -1,200.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -280.00K | -181.29K | 40.15K | 175.80K | 289.95K | 500.46K | 12.53K | 17.62K | 1.26M | 1.11M | 430.00 | 600.00K | -73.09K | 9.17M | -167.91K | 259.65K | -26.72K | -14.51K | -4.33K | -4.67K | -23.51K | -32.28K | -120.98K | 300.00K | 0.00 | -500.00K | -600.00K | -300.00K | -200.00K | 200.00K | 100.00K | 100.00K | -300.00K | -100.00K | 0.00 | 100.00K | 1.80M | 1.70M |
| Net Income | -9.81M | -13.49M | -12.95M | -10.13M | -11.99M | -14.00M | -5.01M | -5.02M | -1.38M | -9.61M | -10.08M | -4.25M | -7.38M | -5.18M | -16.49M | -5.82M | -5.46M | -7.60M | -4.45M | -3.36M | -3.11M | -3.29M | -3.57M | -4.96M | -8.50M | -7.10M | -5.80M | -5.40M | -3.00M | -3.40M | -2.80M | -1.80M | -1.30M | -1.10M | -1.10M | -1.30M | -1.40M | -1.80M | -1.70M |
| Net Income Ratio | -4,671.90% | -0.55% | -2,526.17% | 0.00% | -4,797.78% | -1,258.07% | -1,381.79% | -1,672.14% | -14.90% | -261.94% | -2,592.28% | -452.42% | -735.46% | -708.27% | -1,561.76% | -282.17% | -1,121.12% | -1,494.33% | -1,012.14% | -679.66% | -1,275.24% | -63.34% | -211.26% | -337.24% | -8,500.00% | -7,100.00% | -5,800.00% | -5,400.00% | -3,000.00% | -3,400.00% | -2,800.00% | -1,800.00% | -1,300.00% | -1,100.00% | -1,100.00% | -1,300.00% | -1,400.00% | -1,800.00% | -566.67% |
| EPS | -0.32 | -0.44 | -0.45 | -0.46 | -0.61 | -0.79 | -0.41 | -0.57 | -0.14 | -1.00 | -1.17 | -0.53 | -1.01 | -0.79 | -2.70 | -1.02 | -1.20 | -1.81 | -1.14 | -0.92 | -0.94 | -1.10 | -1.26 | -1.81 | -3.29 | -2.79 | -2.29 | -2.24 | -1.35 | -1.59 | -1.37 | -0.91 | -0.68 | -0.68 | -0.68 | -0.68 | -0.91 | -1.14 | -1.14 |
| EPS Diluted | -0.32 | -0.44 | -0.45 | -0.46 | -0.61 | -0.79 | -0.41 | -0.57 | -0.14 | -1.00 | -1.17 | -0.53 | -1.01 | -0.79 | -2.70 | -1.02 | -1.20 | -1.81 | -1.14 | -0.92 | -0.94 | -1.10 | -1.26 | -1.81 | -3.16 | -2.69 | -2.29 | -2.17 | -1.30 | -1.59 | -1.37 | -0.91 | -0.68 | -0.68 | -0.68 | -0.68 | -0.91 | -1.14 | -1.14 |
| Weighted Avg Shares Out | 30.98M | 30.37M | 28.58M | 22.23M | 19.79M | 17.62M | 12.20M | 8.74M | 9.63M | 9.57M | 8.64M | 7.98M | 7.33M | 6.53M | 6.10M | 5.69M | 4.55M | 4.19M | 3.89M | 3.65M | 3.30M | 2.99M | 2.84M | 2.74M | 2.58M | 2.54M | 2.53M | 2.41M | 2.22M | 2.13M | 2.05M | 1.98M | 1.90M | 1.61M | 1.61M | 1.90M | 1.54M | 1.58M | 1.49M |
| Weighted Avg Shares Out (Dil) | 30.98M | 30.37M | 28.58M | 22.23M | 19.79M | 17.62M | 12.20M | 8.74M | 9.63M | 9.57M | 8.64M | 7.98M | 7.33M | 6.53M | 6.10M | 5.69M | 4.55M | 4.19M | 3.89M | 3.65M | 3.30M | 2.99M | 2.84M | 2.74M | 2.69M | 2.64M | 2.53M | 2.49M | 2.31M | 2.13M | 2.05M | 1.98M | 1.90M | 1.61M | 1.61M | 1.90M | 1.54M | 1.58M | 1.49M |
Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10
SAN JOSE, Calif , Dec. 4, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, announced today that it will be participating in the iAccess Alpha Virtual...
Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
SAN JOSE, Calif. , Nov. 22, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Board of Directors has approved the purchase...
Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial
Third cohort dose is one million CAR positive cells; ten times higher than the first cohort dose SAN JOSE, Calif. , Nov. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on...
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Data continues positive trend as additional patients are enrolled in 3 cohorts Vaccine was safe and well tolerated by participants in all 3 cohorts Protocol defined immune responses were exhibited in over 70% of patients A Phase 2 study evaluating...
Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
SAN JOSE, Calif. , Nov. 6, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the presentation of additional data from the Phase...
Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024
SAN JOSE, Calif. , Oct. 31, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its presentation at the Sidoti Micro-Cap Virtual Conference, taking...
Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
SAN JOSE, Calif. , Oct. 28, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation of additional data from the Phase 1...
Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial
Patient showed clinical activity after initial treatment, with necrosis, inflammation, and T cell infiltration observed in tumor biopsy from the lowest dose SAN JOSE, Calif. , Oct. 15, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX),...
Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development
SAN JOSE, Calif. , Oct. 7, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Suyasha Gupta as Senior Director of...
Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial
Amendment will allow a second dose of CAR-T therapy to suitable patients SAN JOSE, Calif. , Sept. 30, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of...
Source: https://incomestatements.info
Category: Stock Reports